The U.S. Food and Drug Administration requested that manufacturers of GLP‑1 obesity drugs remove warnings about suicidal ideation and behavior from product labeling after a post‑market evaluation found no increased risk. The request covers Lilly’s Zepbound and Novo Nordisk’s Saxenda and Wegovy and follows agency safety reviews. FDA officials said the change is based on aggregated post‑market data and will alter the warnings and precautions sections of labeling. Company statements and FDA correspondence indicate the revision will remove a class‑level language that previously mirrored concerns associated with older weight‑loss medicines. Manufacturers and payers will need to update safety communications and prescribing information; clinicians will watch for FDA instructions on patient monitoring. The move signals a recalibration of post‑market messaging after extensive GLP‑1 uptake and scrutiny from regulators and the public.